Akela Pharma Enrolls First Patient in Asthma Trial
Posted on: Tuesday, 28 August 2007, 12:16 CDT
Akela Pharma has enrolled the first patient in its Phase IIb clinical trial to treat adult patients with mild asthma.
The trial is a multi-centered, double-blind, placebo controlled, randomized cross-over study to evaluate the effects of inhaled CGRP on clinical and inflammatory parameters in adult patients with mild asthma following allergen challenge test.
A total of 16 patients will be enrolled in two randomized one week treatment periods (either 5mg CGRP or placebo).
"Having already successfully demonstrated the CGRP bronchoprotective efficacy for the first time in human asthmatics in the previous Phase IIa study and based on the compelling results previously obtained in pre-clinical studies, we are now looking forward to demonstrating its anti-inflammatory properties," said Dr Halvor Jaeger, CEO of Akela Pharma. "Positive results from this study would confirm CGRP's potential as a strong alternative to the usual combination asthma therapies."
Akela CGRP is a 37 amino acid natural neuropeptide produced in the lung in response to allergic stimuli. As a potential drug, it has demonstrated in preclinical studies a profile that could make it an anti-asthmatic drug candidate with bronchodilatory, bronchoprotecting and anti-inflammatory properties, according to the company.
Source: Datamonitor
Related Articles
- Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies With REOLYSIN(R)
- Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
- New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
- China Begins Clinical Studies on Anti-Viral Drug to Combat Bird Flu
- Antibiotic Utilization and Outcomes for Patients With Clinically Suspected Ventilator-Associated Pneumonia and Negative Quantitative BAL Culture Results*
- Findings Reported From the First Study to Link Patients' Genetic Profiles With Their Clinical Outcomes After Cardiac Operations
- Quality-of-Life Determinants in Patients With Clinically Stable Bronchiectasis*
- Clinical Study Demonstrates That CLEARANT PROCESS(R) Improves ACL Reconstructive Surgery Results; Study of 70 Patients Shows 0% Rate of Infection
- Studies Show Schizophrenia Patients Taking Atypicals Stayed on Treatment Longer Than Patients Taking Older, Typical Antipsychotics
- U. Enlists Patients in Clinical Study Linked to Fatal Lung Disease
 |
 |
User Comments (0)
RSS Feeds